Appendix A
Table A1. Spearman Rho Correlations between Patients’ Characteristics and the Between Group Variable:
Type of Medication to Treat Opioid Use Disorder and the Primary Outcome: Diagnosis of Neonatal Abstinence Syndrome (NAS) Requiring Treatment, N=193
Patient Characteristics
Between Group Variable:
Type of Medication to Treat Opioid Use Disorder
Primary Outcome:
Diagnosis of Neonatal Abstinence Syndrome (NAS)
Requiring Treatment
rho p rho p
Type of Medication to Treat Opioid Use Disorder
na na 0.193 0.007
Age at Delivery -0.041 0.573 0.073 0.316
Race/Ethnicity -0.020 0.782 0.024 0.744
Insurance Type -0.092 0.201 0.045 0.537
Year of Expected Delivery* -0.376 <0.001 -0.154 0.033
Gravidity 0.003 0.964 0.103 0.152
Parity -0.021 0.770 0.070 0.335
History of Physical, Sexual or Emotional Abuse, or Interpersonal Violence
-0.074 0.827 -0.081 0.265
Substance use Disorder Diagnoses 0.105 0.144 0.092 0.205
Chronic Pain Diagnosis -0.015 0.832 0.042 0.562
Concurrent Mental Health Diagnosis -0.111 0.124 0.113 0.116
Medical Comorbidities Pregestational diabetes Chronic hypertension HIV
Hepatitis C*
History of Preterm Delivery
0.055 -0.015 -0.081 -0.013 -0.098
0.451 0.832 0.261 0.860 0.174
0.089 -0.074
0.078 0.153 -0.002
0.218 0.304 0.281 0.034 0.982 Prescriber of Medication to Treat
Opioid Use Disorder*
-0.434 <0.001 -0.216 0.003
Dose of Medication to Treat Opioid Use Disorder at Delivery*
0.171 0.017 0.064 0.377
Tobacco Use in Pregnancy -0.045 0.535 0.018 0.799
Illicit Drug Use and/or Cannabis Use In Pregnancy
Gestational Age at Prenatal Care Initiation with PSUDs Program
-0.016 0.827 -0.081 0.265
Obtained Prenatal Care Elsewhere Prior to PSUDs Program
-0.072 0.318 -0.059 0.418
Notes. Abbreviations: PSUDs is Perinatal substances use disorders *Controlled for in multivariate analysis
1
Table A2. Spearman Rho Correlations between Maternal Prenatal Care Utilization, Delivery Outcomes, and the Primary Outcome: Diagnosis of Neonatal Abstinence Syndrome (NAS) Requiring Treatment, N=193
Maternal Prenatal Care Utilization
Primary Outcome:
Diagnosis of Neonatal Abstinence Syndrome (NAS) Requiring
Treatment
rho p
Attended Expected Number of Visits -0.094 0.193
Pharmacotherapy for Mental Health Diagnosis
0.054 0.459
Pharmacotherapy for medical comorbidities Pre- or Gestational Diabetes
Chronic or gestational Hypertension
0.081 -0.062
0.264 0.395 Maternal Urine Drug Screen at Delivery
Appropriate for Prescribed Medications Only
0.011 0.875
Sex of Baby 0.020 0.787
Preterm Delivery* -0.163 0.023
Low Birth Weight† -0.152 0.035
Cord Toxicology at Birth 0.055 0.495
5-minute APGAR 0.027 0.715
Length at Birth 0.052 0.471
Head Circumference at Birth 0.059 0.418
Notes: *Controlled for in multivariate analysis
† Omitted from multivariate analysis due to significant relationship with preterm delivery, rho=0.497, p<0.001.
2
